FDA Otitis Media Guidance To Offer “Flexible Approach” To Trial Design
FDA's otitis media guidance will offer a "flexible approach" to designing trials for anti-infective drugs being developed for the condition, the agency said
You may also be interested in...
The size of trials for acute otitis media could depend on whether tympanocentesis is used in the design, FDA Anti-Infective Drugs Advisory Committee member James Leggett, MD, Oregon Sciences University, said
Pfizer Zithromax one-day and three-day dosing regimens need more pharmacokinetic studies in children with acute otitis media, FDA's Anti-Infective Drugs Advisory Committee recommended Nov. 7
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011